Jefferies downgraded Exact Sciences Corp (EXAS) to Hold from Buy on November 23, 2025. The stock currently trades at $101.01.
This action reflects increased caution regarding the company's outlook, potentially due to competitive pressures and market conditions that may affect performance. Exact Sciences, a biotechnology firm headquartered in Madison, Wisconsin, specializes in cancer screening and diagnostics. The company employs approximately 6,900 full-time staff and has a market capitalization of $12.7 billion.
Exact Sciences focuses on early cancer detection and treatment guidance, with products including the Cologuard test and Oncotype DX tests. The company is actively developing tests for colorectal cancer, multi-cancer early detection (MCED), and minimal residual disease (MRD).
Looking ahead, Exact Sciences is set to report earnings on August 4, 2026, with an estimated EPS of $0.12 and revenue of $935.7 million. In its most recent quarter, Q3 2025, the company reported an EPS of -$0.10, missing estimates by 40.1%.
Analyst consensus as of November 1, 2025, shows 12 Strong Buy, 14 Buy, and 4 Hold ratings across 30 analysts, indicating a general preference for the stock despite the recent downgrades from multiple firms, including Benchmark, William Blair, Wells Fargo, and Guggenheim.
The announcement highlights the importance of considering a range of factors, including company fundamentals and market trends, when evaluating investment opportunities. Analyst ratings can change over time as new information emerges.